Trial ID or NCT#

NCT03020602

Status

not recruiting iconNOT RECRUITING

Purpose

This phase I trial studies the side effects and best dose of ubidecarenone injectable nanosuspension (BPM31510) in treating patients with high-grade glioma (anaplastic astrocytoma or glioblastoma) that has come back and have been previously treated with bevacizumab. BPM31510 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Official Title

A Phase I Study of BPM31510 Plus Vitamin K in Subjects With High-Grade Glioma That Has Recurred on a Bevacizumab Containing Regimen

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Seema Nagpal, MD
Seema Nagpal, MD
Neuro-oncologist
Clinical Associate Professor, Neurology & Neurological Sciences Clinical Associate Professor (By courtesy), Neurosurgery
Chirag Patel, MD, PhD
Chirag Patel, MD, PhD
Neuro-oncologist
Clinical Assistant Professor, Neurology & Neurological Sciences Clinical Assistant Professor, Radiology - Rad/Molecular Imaging Program at Stanford
Michael Iv
Michael Iv
Radiologist
Clinical Associate Professor, Radiology
Reena Thomas, MD PhD
Reena Thomas, MD PhD
Neuro-oncologist
Clinical Associate Professor, Neurology & Neurological Sciences Clinical Associate Professor (By courtesy), Neurosurgery

Contact us to find out if this trial is right for you.

CONTACT

CCTO
(650) 498-7061